OBJECTIVES: To analyze the association of CHMP2B expression level of with clinicopathological characteristics and prognosis of clear cell renal cell carcinoma (CRCC) and the possible role of CHMP2B in tumorigenesis and progression of CRCC. METHODS: RNAseq data of CRCC were downloaded from the TCGA database for analysis of CHMP2B expression levels in tumor and adjacent tissues and their correlation with clinicopathological characteristics of the patients. Survival outcomes of the patients with high and low CHMP2B expressions were analyzed using the Kaplan-Meier model, and the COX risk regression model was used for identifying the prognostic factors of the patients. The correlation between CHMP2B expression and immune infiltration, its co-expressed genes, and the effect of CHMP2B gene mutations on immunotherapy responses, and its immunohistochemical expression in CRCC and normal tissues were analyzed. Clinical samples of CRCC were collected to examine CHMP2B expressions using RT-PCR, and cell experiment was carried out to test the effect of CHMP2B overexpression on biological behaviors of CRCC cells. RESULTS: CHMP2B was significantly under-expressed in renal cancer tissues, and its overexpression obviously inhibited the proliferation of CRCC cells in vitro. CHMP2B expression level was significantly correlated with age, gender, lymph node metastasis, and tumor stage, and the patients with low CHMP2B expression had poor survival outcomes. Enrichment and co-expression gene analyses suggested that CHMP2B was mainly involved in viral outgrowth, necrotic apoptosis, endocytosis, and immune-regulatory processes in kidney cancer. CONCLUSIONS CHMP2B is lowly expressed in renal cancer tissues to affect tumor progression and tumor immune processes, and may serve as a prognostic biomarker and therapeutic target for CRCC.
Humans ; Carcinoma, Renal Cell/metabolism* ; Kidney Neoplasms/metabolism* ; Cell Proliferation ; Prognosis ; Cell Line, Tumor ; Male ; Female ; Gene Expression Regulation, Neoplastic

Objective To explore the feasibility of a modified technique of extracorporeal appendectomy assisted by transumbilical single-site laparoscopy for non-encapsulated appendicitis in children.Methods Between June 2022 and December 2023,extracorporeal appendectomy assisted by transumbilical single-site laparoscopy was performed in our department for non-encapsulated appendicitis in 30 children(aged from 2 to 6 years old).A 5 mm trocar and a 30° laparoscope were inserted in the center of the umbilicus,and a 5 mm trocar and operating forceps were inserted at the lower edge of the umbilicus.The diseased appendix was explored and located.Non-invasive laparoscopic grasping forceps were used to clamp the head or center of the appendix.The tissue between the two trocar ports was cut open with the use of an electric knife.The appendix and distal cecum were pulled out of abdominal cavity to ligate the appendix root and mesentery.Then the appendix was disconnected with an electric hook.Results The operating time of the 30 cases was 15-22 min(average,18.0±2.5 min).Patients got out of bed and walked around at 6-8 h after surgery,and passed flatus and consumed liquid food within 1 d after surgery.Postoperative hospitalization was 2-5 d(average,3.5 d).Follow-ups for 1-15 months(average,4.5 months)showed no complications such as incision infection,adhesive intestinal obstruction,or pelvic abscess.Conclusion Transumbilical single-site laparoscopy assisted extracorporeal appendectomy is an effective procedure to resect the appendix,with characteristics of handy and convenient performance,being suitable for non-encapsulated appendicitis.

Objective To investigate the safety and efficacy of preoperative ultra-short-course chemotherapy combined with surgical treatment of chest wall tuberculosis. Methods The clinical data of 216 patients with chest wall tuberculosis from January 2013 to June 2016 in our hospital were retrospectively analyzed, including 121 males and 95 females with an average age of 35±15 years (range, 4-74 years). Results All patients were treated with anti-tuberculosis drugs for 17.0±11.3 days preoperatively, including 12.5±5.0 days in simple chest wall tuberculosis and 19.4±12.3 days in combined chest wall tuberculosis. The postoperative recurrence rate of chest wall tuberculosis was 3.7%, which was close to or lower than that of routine preoperative antituberculous therapy in patients with ultra-short-course anti-tuberculosis treatment before surgery. Conclusion Preoperative ultra-short-course chemotherapy combined with surgical treatment for chest wall tuberculosis will not increase the recurrence rate of chest wall tuberculosis, and can effectively shorten the hospital stay. Timely adjustment of anti-tuberculosis chemotherapy based on thorough debridement, postoperative drugs, not the preoperative drugs, is the key to reinforce the surgical outcome.